Active Infection & Immunity NIHR-supported project
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
William Tucker (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
CLARITY : A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Subjects with Moderately to Severely Active Crohn’s Disease (POWER)
A phase ii, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab when given in combination with mycophenolate mofetil and corticosteroids in adolescent participants with active class iii or iv lupus nephritis
D5271C00001 - A 52-Week, Multicentre, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn’s Disease (INTREPID LEAD IN)
A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma
Original classification
Vascular Disease and InflammationPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know